{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:24:46Z","timestamp":1787999086772,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study (\n                      <jats:styled-content style=\"fixed-case\">NCT02471144<\/jats:styled-content>\n                      ), secukinumab treatment for up to 104\u2009weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Final long\u2010term safety and efficacy results of secukinumab through 236\u2009weeks of treatment in paediatric patients with severe chronic plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During the extension period (Weeks 52\u2013236), paediatric patients aged 6 to &lt;18\u2009years with severe chronic plaque psoriasis received either \u2018Any secukinumab\u2019 low dose (LD; patients receiving secukinumab LD up to Week 52; patients on placebo who transitioned to secukinumab LD) or \u2018Any secukinumab\u2019 high dose (HD; patients receiving secukinumab HD up to Week 52 and patients on placebo who transitioned to secukinumab HD). Assessments included Psoriasis Area and Severity Index (PASI) 75\/90\/100 responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0\/1 response, relapse, rebound, Children's Dermatology Life Quality Index (CDLQI) score, CDLQI 0\/1 response and long\u2010term safety up to Week 236.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Secukinumab maintained efficacy through 236\u2009weeks of treatment, with consistent responses observed in most assessments across both dose groups. At Week 236, the responder rate for IGA mod 2011 0\/1 was 69.4% (\u2018Any secukinumab\u2019 LD) and 79.5% (\u2018Any secukinumab\u2019 HD); the PASI 75\/90\/100 responses were 97.2%\/77.8%\/50.0% (\u2018Any secukinumab\u2019 LD) and 97.4%\/84.6%\/69.2% (\u2018Any secukinumab\u2019 HD). CDLQI 0\/1 responses remained consistent in both dose groups and were maintained up to Week 236 (\u2018Any secukinumab\u2019 LD: 64.3%; \u2018Any secukinumab\u2019 HD: 67.7%). The most common adverse events were nasopharyngitis (EAIR\/100 PYs [95% CI]:13.9 [10.0, 18.7]), headache (5.8 [3.7, 8.8]) and tonsillitis (4.7 [2.8, 7.4]).\n                      <jats:italic>Candida<\/jats:italic>\n                      infections were reported in 3 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236\u2010week treatment period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70155","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T11:14:37Z","timestamp":1763205277000},"page":"617-625","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long\u2010term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236\u2010week, Phase 3 trial results"],"prefix":"10.1111","volume":"40","author":[{"given":"Andrzej","family":"Kaszuba","sequence":"first","affiliation":[{"name":"DERMED Medical Services  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philemon","family":"Papanastasiou","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-9870","authenticated-orcid":false,"given":"Dorota","family":"Krasowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology and Pediatric Dermatology, Medical University of Lublin  Lublin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"De Lucas Laguna","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario La Paz  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ziv","sequence":"additional","affiliation":[{"name":"Department of Dermatology Emek Medical Center  Afula Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East\u00a0Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Bansal","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil S.","family":"Dahale","sequence":"additional","affiliation":[{"name":"IQVIA  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East\u00a0Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Paguet","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-0153","authenticated-orcid":false,"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[{"name":"University Hospital M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulli","family":"Kingo","sequence":"additional","affiliation":[{"name":"Tartu University Hospital and University of Tartu  Tartu Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-2985-x"},{"issue":"12","key":"e_1_2_14_8_1","article-title":"Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families","volume":"6","author":"Na CH","year":"2019","journal-title":"Children (Basel)"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00758-2"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563"},{"issue":"8","key":"e_1_2_14_11_1","article-title":"Pediatric psoriasis: from new insights into pathogenesis to updates on treatment","volume":"9","author":"Kim HO","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17002"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19063"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13382"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.056"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0655"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000262"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164858"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2021.10.009"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13091"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_935_20"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1009991"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac040"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.08.066"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233781"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04640-9"},{"key":"e_1_2_14_30_1","volume-title":"Safe and effective medicines for children: pediatric studies conducted under the best Pharmaceuticals for Children act and the pediatric research equity act","author":"Committee on pediatric studies conducted under the best Pharmaceuticals for Children act (BPCA) and the pediatric research equity act (PREA); board on health sciences policy; Institute of Medicine","year":"2012"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:34Z","timestamp":1776868654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/jdv.70155"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70155","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"2025-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}